When UPR inhibitors were combined with TKIs in BCR-ABL+ ALL as well as with proteasome inhibitors in multiple myeloma, a striking synergistic effect occurred in both diseases [19], (Salimi et al., unpublished data). Here, ABL1 is linked to acute lymphoblastic leukemia.